概要
目的
评价蛋白酶抑制剂联合阿比多尔的抗病毒方案在严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 肺炎患者中应用的安全性.
创新点
首次评价了蛋白酶抑制剂联合阿比多尔的抗病毒方案在 SARS-CoV-2 肺炎患者中安全性良好.
方法
回顾性分析了 52 例 SARS-CoV-2 肺炎患者的临床资料, 分析患者入院时以及抗病毒治疗期间症状、 肝功能及血脂水平等的变化.
结论
该方案最常见的不良反应为消化道症状和血脂代谢异常, 血清甘油三酯、总胆固醇和低密度脂蛋白胆固醇水平均较治疗前显著升高; 与洛匹那韦/利托那韦相比, 达芦那韦/考比司他对血脂代谢的负面影响较小; 建议对使用蛋白酶抑制剂联合阿比多尔抗病毒方案的患者密切监测和随访血脂水平变化.
Article PDF
References
Banhegyi D, Katlama C, da Cunha CA, et al., 2012. Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN. Curr HIV Res, 10(2):171–181. https://doi.org/10.2174/157016212799937218
Chan KS, Lai ST, Chu CM, et al., 2003. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J, 9(6):399–406.
Chu CM, Cheng VCC, Hung IFN, et al., 2004. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax, 59(3):252–256. https://doi.org/10.1136/thorax.2003.012658
Huang XJ, Xu LM, Sun LJ, et al., 2019. Six-year immunologic recovery and virological suppression of HIV patients on LPV/r-based second-line antiretroviral treatment: a multicenter real-world cohort study in China. Front Pharmacol, 10:1455. https://doi.org/10.3389/fphar.2019.01455
Khamitov RA, Loginova SI, Shchukina VN, et al., 2008. Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures. Vopr Virusol, 53(4):9–13.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), 2002. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 106(25): 3143–3421. https://doi.org/10.1161/circ.106.25.3143
National Health Commission of the People’s Republic of China, 2020. Diagnosis and treatment of novel coronavirus pneumonia (Trial Version 7) (in Chinese). http://www.nhc.gov.cn/xcs/zhengcwj/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml [Accessed on Mar. 11, 2020].
Omotuyi OI, Nash O, Ajiboye BO, et al., 2020. Darunavir disrupts critical nodes in metastable 2019-nCoV-RBD/ACE-2 complex. Preprints, 2020030125. https://doi.org/10.20944/preprints202003.0125.v1
Orkin C, DeJesus E, Khanlou H, et al., 2013. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. HIV Med, 14(1): 49–59. https://doi.org/10.1111/j.1468-1293.2012.01060.x
Ortiz R, Dejesus E, Khanlou H, et al., 2008. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS, 22(12):1389–1397. https://doi.org/10.1097/QAD.0b013e32830285fb
Ramshanker N, Jessen N, Voss TS, et al., 2019. Effects of short-term prednisolone treatment on indices of lipolysis and lipase signaling in abdominal adipose tissue in healthy humans. Metabolism, 99:1–10. https://doi.org/10.1016/j.metabol.2019.06.013
Wang MZ, Cai BQ, Li LY, et al., 2004. Efficacy and safety of Arbidol in treatment of naturally acquired influenza. Acta Acad Med Sin, 26(3):289–293 (in Chinese).
Xu KJ, Cai HL, Shen YH, et al., 2020. Management of COVID-19: the Zhejiang experience. J Zhejiang Univ (Med Sci), 49(2):147–157 (in Chinese). https://doi.org/10.3785/j.issn.1008-9292.2020.02.02
Xu XW, Wu XX, Jiang XG, et al., 2020. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-CoV-2) outside of Wuhan, China: retrospective case series. BMJ, 368:m606. https://doi.org/10.1136/bmj.m606
Zhou P, Yang XL, Wang XG, et al., 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579(7798):270–273. https://doi.org/10.1038/s41586-020-2012-7
Acknowledgments
All authors participated in the fight against SARS-CoV-2 on the front line, and we especially acknowledge and honor all medical personnel who sacrificed their lives in this battle.
Author information
Authors and Affiliations
Contributions
Kai-jin XU and Biao ZHU designed the study. Yong-zheng GUO coordinated the work, developed the statistical methods, and took the lead in drafting the manuscript and interpreting. Yong-tao LI participated in the data analysis. Jia-dan FU, Min XU, and Ling YU performed the data collection. Ji-fang SHENG participated in writing and editing of the manuscript. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. All authors have read and approved the final manuscript, and therefore, have full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Corresponding author
Additional information
Compliance with ethics guidelines
Yong-zheng GUO, Kai-jin XU, Yong-tao LI, Jia-dan FU, Min XU, Ling YU, Ji-fang SHENG, and Biao ZHU declare that they have no conflict of interest.
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008(5). Informed consent was obtained from all patients for being included in the study.
Project supported by the National Science and Technology Major Project of China During the 13th Five-Year Plan Period (Nos. 2017ZX 10202102 and 2018ZX10715014)
Rights and permissions
About this article
Cite this article
Guo, Yz., Xu, Kj., Li, Yt. et al. Safety of protease inhibitors and Arbidol for SARS-CoV-2 pneumonia in Zhejiang Province, China. J. Zhejiang Univ. Sci. B 21, 948–954 (2020). https://doi.org/10.1631/jzus.B2000204
Published:
Issue Date:
DOI: https://doi.org/10.1631/jzus.B2000204